Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln

(RTTNews) - CSL (CSL.AX) and Alentis Therapeutics have entered into an exclusive global collaboration and co-promotion agreement to advance lixudebart, a potential first-in-class therapy targeting claudin-1 for the treatment of rare kidney, liver and other diseases, CSL said in a

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Health & Medicine

More from Monday 5 October →